Moleculin Biotech is a Phase 3 clinical-stage pharmaceutical company focused on therapeutic candidates for hard-to-treat tumors and viruses. Its lead program is Annamycin, and the company is also developing additional oncology and antiviral candidates including WP1066 and WP1122.
Moleculin Biotech announced a preliminary blinded composite complete remission rate of 40% in the first 30 subjects of its Phase 2B/3 MIRACLE trial testing Annamycin plus cytarabine for relapsed or refractory acute myeloid leukemia.
Moleculin Biotech announced the Japan Patent Office has issued a notice of allowance for a patent covering proprietary methods for reconstituting liposomal Annamycin, strengthening the company's international intellectual property position.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06788756 |
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML |
RECRUITING | PHASE2/PHASE3 |
| NCT05879250 |
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma |
RECRUITING | PHASE2 |
| NCT05319587 |
Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML) |
COMPLETED | PHASE1/PHASE2 |
| NCT05195723 |
Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy Volunteers |
COMPLETED | PHASE1 |
| NCT04887298 |
Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases |
COMPLETED | PHASE1/PHASE2 |
| NCT04702503 |
Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL) |
COMPLETED | PHASE1 |
| NCT03388749 |
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) |
COMPLETED | PHASE1/PHASE2 |
| NCT03315039 |
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) |
COMPLETED | PHASE1/PHASE2 |
